Spots Global Cancer Trial Database for A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Official Title: Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly
Study ID: NCT02564094
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size is 60 individuals.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Plovdiv, , Bulgaria
, Plovdiv, , Bulgaria
, Sofia, , Bulgaria
, Sofia, , Bulgaria
, Sofia, , Bulgaria
, Sofia, , Bulgaria
, Stara Zagora, , Bulgaria
, Varna, , Bulgaria
, Varna, , Bulgaria
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
